Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

Data ReadoutpositiveCagriSematirzepatidePositive

AI Analysis

Summary

Novo Nordisk's CagriSema demonstrated superior weight loss (12.4% vs 9.1%) compared to tirzepatide with non-inferior HbA1c reduction in the REIMAGINE 5 trial for adults with type 2 diabetes.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

CagriSema 1.0 mg/1.0 mg achieved superior weight loss of 12.4% vs tirzepatide 5 mg of 9.1% and non-inferior HbA1c reduction at week 60

Importance:7/10

Sentiment:

0.85

Phase_3Weight_LossType_2_DiabetesClinical_TrialREIMAGINE_5

Related Companies

$NVO

Read the original article

Published by GlobeNewswire Pharma on September 21, 2026 10:24 AM

Read Original